The National Institute for Health and Care Excellence (NICE) sets the standards for NHS treatment in England and Wales. Their guidelines on weight management medications determine who can access treatments like Mounjaro, what criteria must be met, and how treatment should be monitored.
Current NICE Recommendations
NICE technology appraisals and clinical guidelines address pharmacological weight management within a broader framework of obesity care. Key principles include:
- Lifestyle interventions first — diet, physical activity, and behavioural change should be offered before or alongside medication
- BMI thresholds — pharmacotherapy is generally recommended for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities
- Lower thresholds for certain ethnic groups — NICE recognises that South Asian, Chinese, and other Black and minority ethnic groups face higher cardiometabolic risk at lower BMI levels
- Specialist involvement — tier 3 weight management services should be involved for complex cases
Mounjaro in NICE Guidance
NICE has appraised tirzepatide for weight management, considering the SURMOUNT trial evidence alongside cost-effectiveness analyses. The appraisal process evaluates whether the health benefits justify the cost to the NHS, using the quality-adjusted life year (QALY) framework. Patients meeting specific clinical criteria may access Mounjaro through NHS specialist weight management services.
What Criteria Must Be Met
To receive Mounjaro on the NHS for weight management, patients typically need to meet several requirements:
- A BMI meeting the thresholds outlined above
- At least one weight-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnoea, etc.)
- Engagement with a multidisciplinary weight management programme
- Demonstration that lifestyle interventions alone have been insufficient
- Agreement to regular monitoring and follow-up appointments
Treatment Duration and Review
NICE recommends that treatment with weight management medications is reviewed regularly:
- An initial review at 3-6 months to assess response
- Treatment should be continued only if a clinically meaningful weight loss has been achieved (typically at least 5%)
- Ongoing annual reviews to assess continued benefit and tolerability
Private Prescriptions and NICE
NICE guidelines apply specifically to NHS prescribing. Private prescribers may use different criteria, though responsible private practice generally follows similar clinical principles. If you are considering a private prescription, tools like MedsLens can help you compare prices across regulated UK pharmacies.
Keeping Up to Date
NICE regularly updates its guidance as new evidence becomes available. Patients and healthcare professionals can sign up for alerts on the NICE website. The evolving evidence base for GLP-1 therapies means that access criteria and recommendations may broaden over time as more long-term data becomes available.